Meeting · senate
Hearings to examine Novo Nordisk's high prices for Ozempic and Wegovy for patients with diabetes and obesity.
2024-09-24 · 14:00
Source status: Scheduled
Committee
Location
562, Dirksen Senate Office Building
Video
Official published hearing
Congress.gov explicitly associates this publication with this proceeding.
S.Hrg.118-473
WHY IS NOVO NORDISK CHARGING AMERICANS WITH DIABETES AND OBESITY OUTRAGEOUSLY HIGH PRICES FOR OZEMPIC AND WEGOVY
No. 473 · 2024-09-24 · GovInfo record 2025-05-07
Source: https://api.congress.gov/v3/committee-meeting/118/senate/335960